MLN2201
MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human
Integrin β2
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
N/A
-
Synonyms
YFC51.1; LDP-01
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Legos JJ, et al. Pharmacological interventions for stroke: failures and future. Expert Opin Investig Drugs. 2002 May;11(5):603-14. [Content Brief]
[2]. Legos JJ, et al. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr Opin Investig Drugs. 2003 Jul;4(7):847-58. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MLN2201 Related Classifications
HY-P991604 Related Classifications
Powered by Bioz